Annual rank65
Sweden · Healthcare
Medicover
Provides healthcare services based on integrated-care and fee-for-service models, alongside laboratory testing across major clinical-pathology areas.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Care networks, laboratories and patient access
Medicover combines patient care with laboratory diagnostics across Europe and India. Healthcare Services spans employer-funded subscriptions, clinics, hospitals, dentistry, fertility care, mental-health centres and wellbeing facilities. Diagnostic Services links laboratories and local collection points in a hub-and-spoke network, offering routine testing alongside genetics and histopathology. The result is a group that both delivers care and supplies information used along the clinical pathway. On 6 August 2026, Medicover and local partners agreed to sell Medicover Hospitals India; the hospital business remains within the reported group until the conditional transaction closes.
Healthcare services
From an employee benefit to a broad care network
Medicover's original model finances and delivers prepaid healthcare for employers and individuals. It now sits beside fee-for-service and publicly funded care across medical clinics, hospitals, dental practices, fertility clinics, mental-health centres, pharmacies, optical outlets and gyms.
- Healthcare Services Prevention, specialist care, hospitals, dentistry and wellbeing
- Explore the care network Clinics, hospitals, fertility, dental, mental-health and fitness settings
- How care is funded Subscriptions, insurance, fee-for-service and public contracts
- Quality approach How the two divisions organise care and laboratory quality
Laboratory diagnostics
When tissue slides become shareable data
Diagnostic Services offers over 12,000 parameters. Its hub-and-spoke system moves samples to core and specialist laboratories; in histopathology, glass slides can instead be scanned and shared. Medicover's digital platform connects more than 100 pathologists with core laboratories in Serbia, Poland and Romania, allowing difficult tissue cases and second opinions to travel electronically. In Q2 2026, Synevo Ukraine launched what the group calls the country's first AI-assisted cytology screening, combining cytologist expertise with advanced imaging algorithms; the source describes assistance, not autonomous diagnosis or decision governance.
- See Synevo Ukraine's AI-assisted cytology launch A cytologist works with advanced imaging algorithms; no autonomous-diagnosis claim
- Diagnostic Services The laboratory division and its role in clinical decisions
- Inside the hub-and-spoke network Central, regional, hospital and specialist laboratories
- Explore the test menu From clinical chemistry and microbiology to genetics and pathology
- Medicover Genetics Gene panels, reproductive health, oncology and whole-exome testing
- Digital histopathology network Core laboratories, scanners and more than 100 connected pathologists
- ▶ VideoWatch: digital pathology at Medicover The head of histopathology explains how glass slides become remote diagnostic images
Geography and brands
Local names connect a multi-market diagnostic footprint
The diagnostic network operates in fifteen European markets, with brands adapted to local systems: Synevo in Romania and Ukraine, IMD and specialist clinic networks in Germany, and beo-lab in Serbia. Healthcare Services has major operations in Poland and Romania and still includes Medicover Hospitals India at this cutoff. On 6 August 2026, Medicover and local partners agreed to sell 100% of MHI to KKR-managed funds; the sale remains subject to approvals and is expected to close in Q4. The disclosed transaction concerns the MHI hospital platform, so it is not presented as a completed or group-wide India exit.
- Track the conditional MHI sale Signed agreement, 24 hospitals and expected Q4 closing; not a completed exit
- Diagnostic markets and brands Synevo, IMD, beo-lab and other country networks
- Company directory Verified operating companies, hospitals and laboratory businesses by country
- People and clinical partners The workforce and external networks supporting care delivery
- Medicover in brief The two divisions and their international footprint
Operating model and origin
Digital access builds on a Warsaw subscription idea
Medicover uses online ordering, patient applications, remote consultations and laboratory automation to widen access and raise utilisation. Its strategy combines service expansion, laboratory optimisation, technology and selective acquisitions. The origin is memorable: the first Warsaw clinic opened in 1995, and an early logo was sketched on a napkin during a flight to Poland.
- Digital access to care Online ordering, applications, remote consultations and automation
- Mission and strategy Service expansion, operational excellence, technology and acquisitions
- The first Warsaw clinic A prepaid-care concept, a helicopter decision and the napkin logo
- How the model developed Care pathways, remote consultations and later milestones
Official profile sources: 1993-1995 | Medicover · Medicover in brief | Medicover
Current 2026 update
What is changing at Medicover in 2026?
Medicover and local partners have agreed to sell the MHI hospital platform while the group tests two European formats: one Warsaw site combining care, diagnostics and physical activity, and AI-assisted cytology for cervical-cancer screening in Ukraine.
The change in one sentence
The group has agreed a transaction that would narrow its hospital footprint while joining care pathways and diagnostics in new ways.
The MHI transaction remains conditional; Medical Point and Synevo's cytology workflow are operating examples without disclosed rollout or clinical-performance evidence.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Hospital portfolio
The India hospital platform is agreed for sale, not yet sold
On 6 August, Medicover, which owns 66.1% of MHI, and local partners owning 33.9% agreed to sell 100% of the MHI hospital platform to KKR-managed funds. MHI had 24 hospitals, about 4,800 beds, about 11,400 employees and EUR220.5 million LTM revenue at 30 June. The 100%-basis enterprise value is EUR1.2 billion; this is not Medicover's cash receipt. The equity purchase price is about EUR0.95 billion, KKR would also acquire about EUR0.1 billion of Medicover loans and accrued interest, and Medicover expects about EUR0.74 billion total cash proceeds at closing. The transaction follows a 2024 evaluation of a possible listing, which the issuer says the KKR alternative superseded. Closing remains subject to approvals and is expected in Q4 2026. Until then, MHI stays inside the reported group; the intended Poland, Germany and Romania focus remains a post-closing plan.
- Current signal24 hospitals · about 4,800 beds · about 11,400 employees · Q4 closing expected
- Why it mattersA large hospital platform could leave the group, but ownership, cash and the more Europe-focused perimeter do not change until the conditional transaction completes.
- MHI divestment agreement Medicover · 6 August 2026
- MHI transaction and group-focus presentation Medicover · 6 August 2026
02 · Care format
Medical Point puts care, diagnostics and activity at one Warsaw address
Medicover's Q2 Diagnostic Services report introduced Medicover Medical Point in Warsaw, a single location combining medical care, diagnostic testing and physical-activity services. The format makes the group's broad ecosystem tangible by locating three service categories in one physical setting. The issuer does not disclose the site's size, patient volumes, ownership structure or unit economics, and it has not announced a national or international rollout. The evidence therefore supports one integrated Warsaw format, not a chain or a new group-wide operating model. Its importance lies in the combination itself: a place where medical, laboratory and activity services are organised together, while replication and utilisation remain open questions.
- Current signalOne disclosed Warsaw site · care + diagnostics + physical activity · no rollout announced
- Why it mattersThe concept turns Medicover's cross-service model into a physical patient format whose scale and repeatability can now be tested.
- Medical Point and AI-assisted cytology Medicover · 22 July 2026
- Q2 network and operating review Medicover · 22 July 2026
03 · Diagnostics technology
Synevo Ukraine adds AI-assisted cytology with the cytologist in the loop
Synevo Ukraine, within Diagnostic Services, launched what Medicover calls the country's first AI-assisted cytology screening. The Q2 report says the workflow combines a cytologist's expertise with advanced imaging algorithms for cervical-cancer screening. Medicover says the approach supports faster, more reliable and transparent diagnostics; it does not publish sensitivity, specificity, regulatory status or adoption figures. The evidence also does not support autonomous diagnosis: the cytologist remains part of the process and the algorithms support the cytologist's interpretation. Diagnostic Services performed 40.3 million tests in Q2, showing the scale of the surrounding laboratory network rather than validating this individual workflow. The launch is therefore a concrete use of AI inside an existing clinical process, not proof of superior outcomes or national deployment.
- Current signalUkraine launch · cytologist plus imaging algorithms · no disclosed accuracy or adoption data
- Why it mattersIt shows where Medicover is inserting AI into diagnostics while preserving the human clinical role and leaving outcome evidence to later disclosures.
- Medical Point and AI-assisted cytology Medicover · 22 July 2026
- Q2 network and operating review Medicover · 22 July 2026
04 · What to watch
Three questions for the next disclosures
Three questions separate signed direction and single-site launches from completed change.
- MHI closingDoes the transaction clear approvals and close within the expected Q4 2026 window?
- European allocationIf the expected proceeds are received, what network, technology or capacity actions are disclosed in Poland, Germany and Romania?
- Format evidenceDo Medical Point or AI-assisted cytology expand beyond their first disclosed settings, and with what operating or clinical evidence?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 65 | +58% | +541% | +62% |